4.8 Article

Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma

Journal

CELL
Volume 181, Issue 4, Pages 832-+

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2020.03.062

Keywords

-

Funding

  1. Lustgarten Foundation Research Investigator Grant
  2. Cancer Center Support (core) from the NCI [P30-CA016359, P30-CA014051]
  3. Yale Cancer Center
  4. Yale Cancer Innovations Award
  5. NIH Director's New Innovator Award [DP2-CA248136]
  6. National Institute for Health Research, Oxford Biomedical Research Centre
  7. NIH/NIGMS [T32-GM007499]
  8. NICHD [F31-HD097958]
  9. NCI [K07-CA222159, K08-CA2080016]
  10. Bob Parsons Fellowship
  11. Wellcome Senior Fellow in Basic Biomedical Science
  12. Oxford, Wellcome Trust [095101, 200837, 106130, 203141]
  13. Medical Research Council [MR/L020149/1]
  14. European Union Horizon 2020 Programme (T2D Systems)
  15. NIDDK [U01-DK105535, U01-DK085545, P30-DK045735, R01-DK110181]
  16. Wellcome [090532, 098381, 212259]
  17. NIHR [NF-SI-0617-10090]
  18. NIH [R01-GM130847, U01-CA210171]
  19. HIPC [2U19AI089992]
  20. Chan Zuckerberg Initiative [CZF2019-002440]
  21. Hale Family Center for Pancreatic Cancer Research
  22. Lustgarten Foundation
  23. Stand Up To Cancer
  24. Noble Effort Fund
  25. Wexler Family Fund
  26. Promises for Purple
  27. Conquer Cancer Foundation-American Society for Clinical Oncology (CCF-ASCO) Young Investigator Award
  28. NIH Loan Repayment Program
  29. MRC [MR/L020149/1] Funding Source: UKRI

Ask authors/readers for more resources

Obesity is a major modifiable risk factor for pancreatic ductal adenocarcinoma (PDAC), yet how and when obesity contributes to PDAC progression is not well understood. Leveraging an autochthonous mouse model, we demonstrate a causal and reversible role for obesity in early PDAC progression, showing that obesity markedly enhances tumorigenesis, while genetic or dietary induction of weight loss intercepts cancer development. Molecular analyses of human and murine samples define microenvironmental consequences of obesity that foster tumorigenesis rather than new driver gene mutations, including significant pancreatic islet cell adaptation in obesity-associated tumors. Specifically, we identify aberrant beta cell expression of the peptide hormone cholecystokinin (Cck) in response to obesity and show that islet Cck promotes oncogenic Kras-driven pancreatic ductal tumorigenesis. Our studies argue that PDAC progression is driven by local obesity-associated changes in the tumor microenvironment and implicate endocrine-exocrine signaling beyond insulin in PDAC development.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available